An investigation on the anti-tumor properties of FSH 33-53 -Lytic

A new designed hybrid peptide FSH 33-53 -Lytic was synthesized and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor cell membranes disintegration. Through in vitro and vivo study, no significant enhancement on anti-tumor activity was shown compared with Lytic peptide only. We also prepared 18 F-Al-NOTA-MAL-FSH 33-53 -Lytic and use microPET image to observe the FSHR targeting of FSH 33-53 -Lytic. No accumulation in the tumor may explain the failure of FSH 33-53 -Lytic on cancer therapy. In summary, microPET image can provide more accurate and visible information for screening new anti-tumor agents.